These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37600823)

  • 1. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
    Rubinstein JD; O'Brien MM
    Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Bhojwani D; Sposto R; Shah NN; Rodriguez V; Yuan C; Stetler-Stevenson M; O'Brien MM; McNeer JL; Quereshi A; Cabannes A; Schlegel P; Rossig C; Dalla-Pozza L; August K; Alexander S; Bourquin JP; Zwaan M; Raetz EA; Loh ML; Rheingold SR
    Leukemia; 2019 Apr; 33(4):884-892. PubMed ID: 30267011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
    Wynne J; Wright D; Stock W
    Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Kantarjian HM; Boissel N; Papayannidis C; Luskin MR; Stelljes M; Advani AS; Jabbour EJ; Ribera JM; Marks DI
    Cancer; 2024 Nov; 130(21):3631-3646. PubMed ID: 39093036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab Ozogamicin: First Pediatric Approval.
    Dhillon S
    Paediatr Drugs; 2024 Jul; 26(4):459-467. PubMed ID: 38780741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
    O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML
    J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
    An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
    Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips AH; Khoury J; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris RS; Nasr LF; Kriwacki RW; Roberts KG; Konopleva M; Jabbour EJ; Mullighan CG
    Blood; 2024 Jul; 144(1):61-73. PubMed ID: 38551807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    Yurkiewicz IR; Muffly L; Liedtke M
    Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
    Fingrut W; Davis W; McGinnis E; Dallas K; Ramadan K; Merkeley H; Leitch H; Abou Mourad Y; Cassaday RD; Ross C; Léger C
    Curr Oncol; 2020 Dec; 28(1):252-259. PubMed ID: 33704192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
    Uy N; Nadeau M; Stahl M; Zeidan AM
    J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
    George B; Kantarjian H; Jabbour E; Jain N
    Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
    Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
    Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.